Company Description
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States.
The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma.
It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial.
In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Stacy Lindborg |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | 609 896 9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| CUSIP Number | 15117N701 |
| ISIN Number | US15117N7012 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Stacy R. Lindborg Ph.D. | President, Chief Executive Officer and Director |
| Michael H. Tardugno | Executive Chairman |
| Dr. Douglas V. Faller M.D., Ph.D. | Chief Medical Officer |
| Susan Mary Eylward | General Counsel and Corporate Secretary |
| Kristin Longobardi M.B.A. | Senior Vice President of Strategic Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 4, 2026 | ARS | Filing |
| May 4, 2026 | 8-K | Current Report |
| May 4, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 424B5 | Filing |